Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sweet vernal, orchard, perennial rye, timothy, and kentucky blue grass mixed pollens allergen extract is an immunotherapy product used for the treatment of grass pollen-induced allergic rhinitis, with or without conjunctivitis. [6, 11] Marketed under the brand name Oralair, it is a sublingual tablet containing extracts from five common types of grass: Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass. [2, 11, 19] The exact mechanism of action is unknown, but it is believed to work by modulating the immune system's response to grass pollen allergens, inducing tolerance and thereby reducing allergic symptoms. [1, 2, 6] Treatment is typically initiated four months prior to the start of the grass pollen season and continued throughout the season. [2, 11] The first dose is administered under medical supervision. [4, 11] The product is developed and manufactured by Stallergenes Greer and was first approved by the FDA in 2014. [4, 26]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sweet vernal, orchard, perennial rye, timothy, and kentucky blue grass mixed pollens allergen extract.